Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3 View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2007-01

AUTHORS

Natalia V. Sergina, Megan Rausch, Donghui Wang, Jimmy Blair, Byron Hann, Kevan M. Shokat, Mark M. Moasser

ABSTRACT

Oncogenic tyrosine kinases have proved to be promising targets for the development of highly effective anticancer drugs. However, tyrosine kinase inhibitors (TKIs) against the human epidermal growth factor receptor (HER) family show only limited activity against HER2-driven breast cancers, despite effective inhibition of epidermal growth factor receptor (EGFR) and HER2 in vivo. The reasons for this are unclear. Signalling in trans is a key feature of this multimember family and the critically important phosphatidylinositol-3-OH kinase (PI(3)K)/Akt pathway is driven predominantly through transphosphorylation of the kinase-inactive HER3 (refs 9, 10). Here we show that HER3 and consequently PI(3)K/Akt signalling evade inhibition by current HER-family TKIs in vitro and in tumours in vivo. This is due to a compensatory shift in the HER3 phosphorylation-dephosphorylation equilibrium, driven by increased membrane HER3 expression driving the phosphorylation reaction and by reduced HER3 phosphatase activity impeding the dephosphorylation reaction. These compensatory changes are driven by Akt-mediated negative-feedback signalling. Although HER3 is not a direct target of TKIs, HER3 substrate resistance undermines their efficacy and has thus far gone undetected. The experimental abrogation of HER3 resistance by small interfering RNA knockdown restores potent pro-apoptotic activity to otherwise cytostatic HER TKIs, re-affirming the oncogene-addicted nature of HER2-driven tumours and the therapeutic promise of this oncoprotein target. However, because HER3 signalling is buffered against an incomplete inhibition of HER2 kinase, much more potent TKIs or combination strategies are required to silence oncogenic HER2 signalling effectively. The biologic marker with which to assess the efficacy of HER TKIs should be the transphosphorylation of HER3 rather than autophosphorylation. More... »

PAGES

437

Journal

TITLE

Nature

ISSUE

7126

VOLUME

445

Related Patents

  • Combinations Of A Mek Inhibitor Compound With An Her3/Egfr Inhibitor Compound And Methods Of Use
  • Predicting Tumor Response To Anti-Erbb3 Antibodies
  • Antibody That Binds Erbb-2 And Erbb-3
  • Immunotherapy Against Several Tumors Including Gastrointestinal And Gastric Cancer
  • Novel Immunotherapy Against Several Tumors Including Gastrointestinal And Gastric Cancer
  • Erbb-3 (Her3)-Selective Combination Therapy
  • Human Serum Albumin Linkers And Conjugates Thereof
  • Methods Of Determining Patient Response By Measurement Of Her-3
  • Compositions And Methods For Treating Cancer Resistant To A Tyrosine Kinase Inhibitor (Tki)
  • Her3 As A Determinant For The Prognosis Of Melanoma
  • Methods Of Treating Cancers With Her3 Antisense Oligonucleotides
  • Methods Of Treating Cancers With Her3 Antisense Oligonucleotides
  • Anti-Erbb3 Antibodies And Uses Thereof
  • Anti-Erbb3 Antibodies And Uses Thereof
  • Immunotherapy Against Several Tumors Including Gastrointestinal And Gastric Cancer
  • Anti-Erbb3 Antibodies And Uses Thereof
  • Immunotherapy Against Several Tumors Including Gastrointestinal And Gastric Cancer
  • Erbb-3 (Her3)-Selective Combination Therapy
  • Her-3 Antibodies And Methods Of Use
  • Compositions And Methods For Treating Cancer Resistant To A Tyrosine Kinase Inhibitor (Tki)
  • Immunotherapy Against Several Tumors Including Gastrointestinal And Gastric Cancer
  • Methods Of Treating Cancers With Her3 Antisense Oligonucleotides
  • Methods And Assays For Measuring P95 And/Or P95 Complexes In A Sample And Antibodies Specific For P95
  • Methods For Treating Cancer Resistant To Erbb Therapeutics
  • Methods And Compositions Comprising A Combination Of An Anti-Erbb3 Antibody And An Anti-Egfr Antibody
  • Antigen Binding Proteins
  • Targeting Her2 And Her3 With Bispecific Antibodies In Cancerous Cells
  • Combination Therapies Comprising Anti-Erbb3 Agents
  • Methods Of Determining Patient Response By Measurement Of Her-3 And P95
  • Use Of 2-Carboxamide Cycloamino Urea Derivatives In The Treatment Of Egfr Dependent Diseases Or Diseases That Have Acquired Resistance To Agents That Target Egfr Family Members
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1038/nature05474

    DOI

    http://dx.doi.org/10.1038/nature05474

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1008085582

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/17206155


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0601", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Biochemistry and Cell Biology", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/06", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Biological Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Breast Neoplasms", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "ErbB Receptors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Feedback, Physiological", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Phosphatidylinositol 3-Kinases", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Phosphorylation", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Proto-Oncogene Proteins c-akt", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Receptor, ErbB-2", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Receptor, ErbB-3", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Signal Transduction", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Substrate Specificity", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "name": [
                "Department of Medicine,"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Sergina", 
            "givenName": "Natalia V.", 
            "id": "sg:person.0746460433.13", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0746460433.13"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "name": [
                "Department of Medicine,"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Rausch", 
            "givenName": "Megan", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "name": [
                "Department of Medicine,"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Wang", 
            "givenName": "Donghui", 
            "id": "sg:person.016020031637.47", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016020031637.47"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "University of California, San Francisco", 
              "id": "https://www.grid.ac/institutes/grid.266102.1", 
              "name": [
                "Department of Cellular and Molecular Pharmacology, University of California, San Francisco 94143, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Blair", 
            "givenName": "Jimmy", 
            "id": "sg:person.01137702207.01", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01137702207.01"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "name": [
                "Department of Medicine,"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Hann", 
            "givenName": "Byron", 
            "id": "sg:person.01245250633.29", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01245250633.29"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "University of California, San Francisco", 
              "id": "https://www.grid.ac/institutes/grid.266102.1", 
              "name": [
                "Department of Cellular and Molecular Pharmacology, University of California, San Francisco 94143, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Shokat", 
            "givenName": "Kevan M.", 
            "id": "sg:person.01243230250.34", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01243230250.34"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "name": [
                "Department of Medicine,"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Moasser", 
            "givenName": "Mark M.", 
            "id": "sg:person.0636073133.00", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0636073133.00"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "https://doi.org/10.1002/ijc.1557", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1004516627"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1206388", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1004564925", 
              "https://doi.org/10.1038/sj.onc.1206388"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1206388", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1004564925", 
              "https://doi.org/10.1038/sj.onc.1206388"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1083/jcb.200109033", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1006703892"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1126/science.1075762", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1006952665"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/s1097-2765(02)00445-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1008968388"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1093/jnci/dji161", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1015799533"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1128/mcb.14.6.3550", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1019691533"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1056/nejmoa011573", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1019929576"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1158/1535-7163.mct-04-0329", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1023219733"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1073/pnas.95.20.12022", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1023432159"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1200/jco.2005.08.326", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1027318783"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0092-8674(88)90184-5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1033937977"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/s0093-7754(03)70011-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1035318488"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1200/jco.2005.12.157", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1036962943"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/s1535-6108(02)00212-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1041691507"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/j.cell.2005.05.016", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1050794846"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/jcp.10411", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1051381849"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1021/jm0005555", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1055933817"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1021/jm0005555", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1055933817"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1126/science.3798106", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1062621480"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1074889449", 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1074963914", 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1075266190", 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1076580382", 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1082569444", 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2007-01", 
        "datePublishedReg": "2007-01-01", 
        "description": "Oncogenic tyrosine kinases have proved to be promising targets for the development of highly effective anticancer drugs. However, tyrosine kinase inhibitors (TKIs) against the human epidermal growth factor receptor (HER) family show only limited activity against HER2-driven breast cancers, despite effective inhibition of epidermal growth factor receptor (EGFR) and HER2 in vivo. The reasons for this are unclear. Signalling in trans is a key feature of this multimember family and the critically important phosphatidylinositol-3-OH kinase (PI(3)K)/Akt pathway is driven predominantly through transphosphorylation of the kinase-inactive HER3 (refs 9, 10). Here we show that HER3 and consequently PI(3)K/Akt signalling evade inhibition by current HER-family TKIs in vitro and in tumours in vivo. This is due to a compensatory shift in the HER3 phosphorylation-dephosphorylation equilibrium, driven by increased membrane HER3 expression driving the phosphorylation reaction and by reduced HER3 phosphatase activity impeding the dephosphorylation reaction. These compensatory changes are driven by Akt-mediated negative-feedback signalling. Although HER3 is not a direct target of TKIs, HER3 substrate resistance undermines their efficacy and has thus far gone undetected. The experimental abrogation of HER3 resistance by small interfering RNA knockdown restores potent pro-apoptotic activity to otherwise cytostatic HER TKIs, re-affirming the oncogene-addicted nature of HER2-driven tumours and the therapeutic promise of this oncoprotein target. However, because HER3 signalling is buffered against an incomplete inhibition of HER2 kinase, much more potent TKIs or combination strategies are required to silence oncogenic HER2 signalling effectively. The biologic marker with which to assess the efficacy of HER TKIs should be the transphosphorylation of HER3 rather than autophosphorylation.", 
        "genre": "research_article", 
        "id": "sg:pub.10.1038/nature05474", 
        "inLanguage": [
          "en"
        ], 
        "isAccessibleForFree": true, 
        "isFundedItemOf": [
          {
            "id": "sg:grant.2478853", 
            "type": "MonetaryGrant"
          }, 
          {
            "id": "sg:grant.2454322", 
            "type": "MonetaryGrant"
          }
        ], 
        "isPartOf": [
          {
            "id": "sg:journal.1018957", 
            "issn": [
              "0090-0028", 
              "1476-4687"
            ], 
            "name": "Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "7126", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "445"
          }
        ], 
        "name": "Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3", 
        "pagination": "437", 
        "productId": [
          {
            "name": "readcube_id", 
            "type": "PropertyValue", 
            "value": [
              "268517a00eb9d29a7d564562e8919c10e33b955bf0488833018c9c9e7324ac6a"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "17206155"
            ]
          }, 
          {
            "name": "nlm_unique_id", 
            "type": "PropertyValue", 
            "value": [
              "0410462"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1038/nature05474"
            ]
          }, 
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1008085582"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1038/nature05474", 
          "https://app.dimensions.ai/details/publication/pub.1008085582"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2019-04-11T12:14", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000361_0000000361/records_54008_00000000.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://www.nature.com/articles/nature05474"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/nature05474'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/nature05474'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/nature05474'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/nature05474'


     

    This table displays all metadata directly associated to this object as RDF triples.

    232 TRIPLES      21 PREDICATES      63 URIs      31 LITERALS      19 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1038/nature05474 schema:about N09b6d17b936445479fad415966ade0df
    2 N1884732cd40249e880b0c8e714b35f0d
    3 N4cedffee8f5e4a2aa605526b19e906ae
    4 N56be69c8be5c465790cfa09b89a1a082
    5 N7421759dea4944d9a95c36a61b70d20b
    6 Nafad089b7fd14830929fc39a5bfcec72
    7 Nc0688658f0c5434ba7b35e8690fe80f3
    8 Nde147680ee4144aab40d6d66fe8850a4
    9 Ne895649895e0447db6fcf47617ec6411
    10 Nf2f35a4b3e8848008ae5af332f1b93ef
    11 anzsrc-for:06
    12 anzsrc-for:0601
    13 schema:author N1a4be3c441b943d0bd67404de62a1750
    14 schema:citation sg:pub.10.1038/sj.onc.1206388
    15 https://app.dimensions.ai/details/publication/pub.1074889449
    16 https://app.dimensions.ai/details/publication/pub.1074963914
    17 https://app.dimensions.ai/details/publication/pub.1075266190
    18 https://app.dimensions.ai/details/publication/pub.1076580382
    19 https://app.dimensions.ai/details/publication/pub.1082569444
    20 https://doi.org/10.1002/ijc.1557
    21 https://doi.org/10.1002/jcp.10411
    22 https://doi.org/10.1016/0092-8674(88)90184-5
    23 https://doi.org/10.1016/j.cell.2005.05.016
    24 https://doi.org/10.1016/s0093-7754(03)70011-6
    25 https://doi.org/10.1016/s1097-2765(02)00445-8
    26 https://doi.org/10.1016/s1535-6108(02)00212-x
    27 https://doi.org/10.1021/jm0005555
    28 https://doi.org/10.1056/nejmoa011573
    29 https://doi.org/10.1073/pnas.95.20.12022
    30 https://doi.org/10.1083/jcb.200109033
    31 https://doi.org/10.1093/jnci/dji161
    32 https://doi.org/10.1126/science.1075762
    33 https://doi.org/10.1126/science.3798106
    34 https://doi.org/10.1128/mcb.14.6.3550
    35 https://doi.org/10.1158/1535-7163.mct-04-0329
    36 https://doi.org/10.1200/jco.2005.08.326
    37 https://doi.org/10.1200/jco.2005.12.157
    38 schema:datePublished 2007-01
    39 schema:datePublishedReg 2007-01-01
    40 schema:description Oncogenic tyrosine kinases have proved to be promising targets for the development of highly effective anticancer drugs. However, tyrosine kinase inhibitors (TKIs) against the human epidermal growth factor receptor (HER) family show only limited activity against HER2-driven breast cancers, despite effective inhibition of epidermal growth factor receptor (EGFR) and HER2 in vivo. The reasons for this are unclear. Signalling in trans is a key feature of this multimember family and the critically important phosphatidylinositol-3-OH kinase (PI(3)K)/Akt pathway is driven predominantly through transphosphorylation of the kinase-inactive HER3 (refs 9, 10). Here we show that HER3 and consequently PI(3)K/Akt signalling evade inhibition by current HER-family TKIs in vitro and in tumours in vivo. This is due to a compensatory shift in the HER3 phosphorylation-dephosphorylation equilibrium, driven by increased membrane HER3 expression driving the phosphorylation reaction and by reduced HER3 phosphatase activity impeding the dephosphorylation reaction. These compensatory changes are driven by Akt-mediated negative-feedback signalling. Although HER3 is not a direct target of TKIs, HER3 substrate resistance undermines their efficacy and has thus far gone undetected. The experimental abrogation of HER3 resistance by small interfering RNA knockdown restores potent pro-apoptotic activity to otherwise cytostatic HER TKIs, re-affirming the oncogene-addicted nature of HER2-driven tumours and the therapeutic promise of this oncoprotein target. However, because HER3 signalling is buffered against an incomplete inhibition of HER2 kinase, much more potent TKIs or combination strategies are required to silence oncogenic HER2 signalling effectively. The biologic marker with which to assess the efficacy of HER TKIs should be the transphosphorylation of HER3 rather than autophosphorylation.
    41 schema:genre research_article
    42 schema:inLanguage en
    43 schema:isAccessibleForFree true
    44 schema:isPartOf N00ffcd39542340a4b7ca50cdc9fa0c81
    45 N91ab38af699645e6b34920f199c32951
    46 sg:journal.1018957
    47 schema:name Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
    48 schema:pagination 437
    49 schema:productId N3d9a59acda6c46f68dc357b9ad5de0b0
    50 N963ddbcd019f43d28378f68f36f24d34
    51 Na93dae039ff549d38afe49d9a91dd585
    52 Ncf6e595ee83c4cecbb035a00f63b3e6f
    53 Neab054e0223e4c57993eb49ebbb2196d
    54 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008085582
    55 https://doi.org/10.1038/nature05474
    56 schema:sdDatePublished 2019-04-11T12:14
    57 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    58 schema:sdPublisher Nc4b4eaee6b5a4188bb789a408d60d067
    59 schema:url https://www.nature.com/articles/nature05474
    60 sgo:license sg:explorer/license/
    61 sgo:sdDataset articles
    62 rdf:type schema:ScholarlyArticle
    63 N00ffcd39542340a4b7ca50cdc9fa0c81 schema:volumeNumber 445
    64 rdf:type schema:PublicationVolume
    65 N09949a7eb4f747fcb91c0bac5e3523d9 rdf:first sg:person.01245250633.29
    66 rdf:rest N456c1f03a3ea48e9a553a816a2e280eb
    67 N09b6d17b936445479fad415966ade0df schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    68 schema:name ErbB Receptors
    69 rdf:type schema:DefinedTerm
    70 N1884732cd40249e880b0c8e714b35f0d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    71 schema:name Receptor, ErbB-3
    72 rdf:type schema:DefinedTerm
    73 N1a4be3c441b943d0bd67404de62a1750 rdf:first sg:person.0746460433.13
    74 rdf:rest Ncbf7eb1d52ab4134a13d63c9486577ca
    75 N1c5ddee2829e419baab4903d7033db50 schema:name Department of Medicine,
    76 rdf:type schema:Organization
    77 N3d9a59acda6c46f68dc357b9ad5de0b0 schema:name dimensions_id
    78 schema:value pub.1008085582
    79 rdf:type schema:PropertyValue
    80 N456c1f03a3ea48e9a553a816a2e280eb rdf:first sg:person.01243230250.34
    81 rdf:rest N46ced4df3cfd435dbd8ad4f9b0475ef7
    82 N46ced4df3cfd435dbd8ad4f9b0475ef7 rdf:first sg:person.0636073133.00
    83 rdf:rest rdf:nil
    84 N4cedffee8f5e4a2aa605526b19e906ae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    85 schema:name Receptor, ErbB-2
    86 rdf:type schema:DefinedTerm
    87 N56be69c8be5c465790cfa09b89a1a082 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    88 schema:name Breast Neoplasms
    89 rdf:type schema:DefinedTerm
    90 N6906e13802a24a0e916b56f565dc3d6c schema:name Department of Medicine,
    91 rdf:type schema:Organization
    92 N6d84e02dec704cf694e1514072b3dc84 rdf:first sg:person.01137702207.01
    93 rdf:rest N09949a7eb4f747fcb91c0bac5e3523d9
    94 N7297ee197b17484f929902dc637ff621 schema:name Department of Medicine,
    95 rdf:type schema:Organization
    96 N7421759dea4944d9a95c36a61b70d20b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    97 schema:name Phosphorylation
    98 rdf:type schema:DefinedTerm
    99 N75b1348011104e93b0a20fc1f29e4886 schema:name Department of Medicine,
    100 rdf:type schema:Organization
    101 N91ab38af699645e6b34920f199c32951 schema:issueNumber 7126
    102 rdf:type schema:PublicationIssue
    103 N963ddbcd019f43d28378f68f36f24d34 schema:name pubmed_id
    104 schema:value 17206155
    105 rdf:type schema:PropertyValue
    106 Na93dae039ff549d38afe49d9a91dd585 schema:name readcube_id
    107 schema:value 268517a00eb9d29a7d564562e8919c10e33b955bf0488833018c9c9e7324ac6a
    108 rdf:type schema:PropertyValue
    109 Nafad089b7fd14830929fc39a5bfcec72 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    110 schema:name Substrate Specificity
    111 rdf:type schema:DefinedTerm
    112 Nb6b7e190916c4864a7417d9a27acd67f rdf:first sg:person.016020031637.47
    113 rdf:rest N6d84e02dec704cf694e1514072b3dc84
    114 Nbf0809fc2fb146c1915e1f3770be9adb schema:affiliation N6906e13802a24a0e916b56f565dc3d6c
    115 schema:familyName Rausch
    116 schema:givenName Megan
    117 rdf:type schema:Person
    118 Nc0688658f0c5434ba7b35e8690fe80f3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    119 schema:name Phosphatidylinositol 3-Kinases
    120 rdf:type schema:DefinedTerm
    121 Nc4b4eaee6b5a4188bb789a408d60d067 schema:name Springer Nature - SN SciGraph project
    122 rdf:type schema:Organization
    123 Ncbf7eb1d52ab4134a13d63c9486577ca rdf:first Nbf0809fc2fb146c1915e1f3770be9adb
    124 rdf:rest Nb6b7e190916c4864a7417d9a27acd67f
    125 Ncf6e595ee83c4cecbb035a00f63b3e6f schema:name doi
    126 schema:value 10.1038/nature05474
    127 rdf:type schema:PropertyValue
    128 Nde147680ee4144aab40d6d66fe8850a4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    129 schema:name Proto-Oncogene Proteins c-akt
    130 rdf:type schema:DefinedTerm
    131 Ne895649895e0447db6fcf47617ec6411 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    132 schema:name Feedback, Physiological
    133 rdf:type schema:DefinedTerm
    134 Neab054e0223e4c57993eb49ebbb2196d schema:name nlm_unique_id
    135 schema:value 0410462
    136 rdf:type schema:PropertyValue
    137 Nf2f35a4b3e8848008ae5af332f1b93ef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    138 schema:name Signal Transduction
    139 rdf:type schema:DefinedTerm
    140 Nf6f24532eec24079985295587267714b schema:name Department of Medicine,
    141 rdf:type schema:Organization
    142 anzsrc-for:06 schema:inDefinedTermSet anzsrc-for:
    143 schema:name Biological Sciences
    144 rdf:type schema:DefinedTerm
    145 anzsrc-for:0601 schema:inDefinedTermSet anzsrc-for:
    146 schema:name Biochemistry and Cell Biology
    147 rdf:type schema:DefinedTerm
    148 sg:grant.2454322 http://pending.schema.org/fundedItem sg:pub.10.1038/nature05474
    149 rdf:type schema:MonetaryGrant
    150 sg:grant.2478853 http://pending.schema.org/fundedItem sg:pub.10.1038/nature05474
    151 rdf:type schema:MonetaryGrant
    152 sg:journal.1018957 schema:issn 0090-0028
    153 1476-4687
    154 schema:name Nature
    155 rdf:type schema:Periodical
    156 sg:person.01137702207.01 schema:affiliation https://www.grid.ac/institutes/grid.266102.1
    157 schema:familyName Blair
    158 schema:givenName Jimmy
    159 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01137702207.01
    160 rdf:type schema:Person
    161 sg:person.01243230250.34 schema:affiliation https://www.grid.ac/institutes/grid.266102.1
    162 schema:familyName Shokat
    163 schema:givenName Kevan M.
    164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01243230250.34
    165 rdf:type schema:Person
    166 sg:person.01245250633.29 schema:affiliation N1c5ddee2829e419baab4903d7033db50
    167 schema:familyName Hann
    168 schema:givenName Byron
    169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01245250633.29
    170 rdf:type schema:Person
    171 sg:person.016020031637.47 schema:affiliation N75b1348011104e93b0a20fc1f29e4886
    172 schema:familyName Wang
    173 schema:givenName Donghui
    174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016020031637.47
    175 rdf:type schema:Person
    176 sg:person.0636073133.00 schema:affiliation Nf6f24532eec24079985295587267714b
    177 schema:familyName Moasser
    178 schema:givenName Mark M.
    179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0636073133.00
    180 rdf:type schema:Person
    181 sg:person.0746460433.13 schema:affiliation N7297ee197b17484f929902dc637ff621
    182 schema:familyName Sergina
    183 schema:givenName Natalia V.
    184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0746460433.13
    185 rdf:type schema:Person
    186 sg:pub.10.1038/sj.onc.1206388 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004564925
    187 https://doi.org/10.1038/sj.onc.1206388
    188 rdf:type schema:CreativeWork
    189 https://app.dimensions.ai/details/publication/pub.1074889449 schema:CreativeWork
    190 https://app.dimensions.ai/details/publication/pub.1074963914 schema:CreativeWork
    191 https://app.dimensions.ai/details/publication/pub.1075266190 schema:CreativeWork
    192 https://app.dimensions.ai/details/publication/pub.1076580382 schema:CreativeWork
    193 https://app.dimensions.ai/details/publication/pub.1082569444 schema:CreativeWork
    194 https://doi.org/10.1002/ijc.1557 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004516627
    195 rdf:type schema:CreativeWork
    196 https://doi.org/10.1002/jcp.10411 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051381849
    197 rdf:type schema:CreativeWork
    198 https://doi.org/10.1016/0092-8674(88)90184-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033937977
    199 rdf:type schema:CreativeWork
    200 https://doi.org/10.1016/j.cell.2005.05.016 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050794846
    201 rdf:type schema:CreativeWork
    202 https://doi.org/10.1016/s0093-7754(03)70011-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035318488
    203 rdf:type schema:CreativeWork
    204 https://doi.org/10.1016/s1097-2765(02)00445-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008968388
    205 rdf:type schema:CreativeWork
    206 https://doi.org/10.1016/s1535-6108(02)00212-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1041691507
    207 rdf:type schema:CreativeWork
    208 https://doi.org/10.1021/jm0005555 schema:sameAs https://app.dimensions.ai/details/publication/pub.1055933817
    209 rdf:type schema:CreativeWork
    210 https://doi.org/10.1056/nejmoa011573 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019929576
    211 rdf:type schema:CreativeWork
    212 https://doi.org/10.1073/pnas.95.20.12022 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023432159
    213 rdf:type schema:CreativeWork
    214 https://doi.org/10.1083/jcb.200109033 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006703892
    215 rdf:type schema:CreativeWork
    216 https://doi.org/10.1093/jnci/dji161 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015799533
    217 rdf:type schema:CreativeWork
    218 https://doi.org/10.1126/science.1075762 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006952665
    219 rdf:type schema:CreativeWork
    220 https://doi.org/10.1126/science.3798106 schema:sameAs https://app.dimensions.ai/details/publication/pub.1062621480
    221 rdf:type schema:CreativeWork
    222 https://doi.org/10.1128/mcb.14.6.3550 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019691533
    223 rdf:type schema:CreativeWork
    224 https://doi.org/10.1158/1535-7163.mct-04-0329 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023219733
    225 rdf:type schema:CreativeWork
    226 https://doi.org/10.1200/jco.2005.08.326 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027318783
    227 rdf:type schema:CreativeWork
    228 https://doi.org/10.1200/jco.2005.12.157 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036962943
    229 rdf:type schema:CreativeWork
    230 https://www.grid.ac/institutes/grid.266102.1 schema:alternateName University of California, San Francisco
    231 schema:name Department of Cellular and Molecular Pharmacology, University of California, San Francisco 94143, USA
    232 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...